Access in all areas? A round up of developments in market access and HTA: part 5.

IF 1.9 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Journal of comparative effectiveness research Pub Date : 2024-11-01 Epub Date: 2024-10-01 DOI:10.57264/cer-2024-0179

Alice Beattie, Francisco Olivença, Catrin Treharne, Sreeram V Ramagopalan

引用次数: 0

Abstract

In this latest update, we explore the recent announcement by Canada's Drug Agency (CDA-AMC, formerly CADTH) on their pilot to include the societal perspective in the evaluation of certain new medicines; a recent Office of Health Economics (OHE) report on the evaluation of HTA agency methods over time; and publications examining the impact of Project Orbis on patient access to oncology treatments.

查看原文本刊更多论文

所有领域的准入？市场准入和 HTA 发展综述：第 5 部分。

在这篇最新文章中，我们探讨了加拿大药品管理局（CDA-AMC，前身为 CADTH）最近宣布的将社会视角纳入某些新药评估的试点项目；卫生经济学办公室（OHE）最近发布的关于长期评估 HTA 机构方法的报告；以及研究奥比斯项目（Project Orbis）对患者获得肿瘤治疗的影响的出版物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of comparative effectiveness research HEALTH CARE SCIENCES & SERVICES-

CiteScore

3.50

自引率

9.50%

发文量

121

期刊介绍： Journal of Comparative Effectiveness Research provides a rapid-publication platform for debate, and for the presentation of new findings and research methodologies. Through rigorous evaluation and comprehensive coverage, the Journal of Comparative Effectiveness Research provides stakeholders (including patients, clinicians, healthcare purchasers, and health policy makers) with the key data and opinions to make informed and specific decisions on clinical practice.